CA2846240C - Antibodies that bind integrin alpha-v beta-8 - Google Patents

Antibodies that bind integrin alpha-v beta-8 Download PDF

Info

Publication number
CA2846240C
CA2846240C CA2846240A CA2846240A CA2846240C CA 2846240 C CA2846240 C CA 2846240C CA 2846240 A CA2846240 A CA 2846240A CA 2846240 A CA2846240 A CA 2846240A CA 2846240 C CA2846240 C CA 2846240C
Authority
CA
Canada
Prior art keywords
antibody
seq
disease
beta
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2846240A
Other languages
English (en)
French (fr)
Other versions
CA2846240A1 (en
Inventor
Stephen Nishimura
Jianlong Lou
Jody Lynn Baron
James Marks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CA2846240A1 publication Critical patent/CA2846240A1/en
Application granted granted Critical
Publication of CA2846240C publication Critical patent/CA2846240C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2846240A 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8 Active CA2846240C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524708P 2011-08-17 2011-08-17
US61/524,708 2011-08-17
US201261646111P 2012-05-11 2012-05-11
US61/646,111 2012-05-11
PCT/US2012/051373 WO2013026004A2 (en) 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8

Publications (2)

Publication Number Publication Date
CA2846240A1 CA2846240A1 (en) 2013-02-21
CA2846240C true CA2846240C (en) 2021-01-12

Family

ID=47715714

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2846240A Active CA2846240C (en) 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8

Country Status (13)

Country Link
US (1) US9492569B2 (enExample)
EP (1) EP2744823B1 (enExample)
JP (1) JP6093360B2 (enExample)
KR (1) KR102010098B1 (enExample)
CN (1) CN103857696B (enExample)
AU (1) AU2012296362B2 (enExample)
BR (1) BR112014003501B1 (enExample)
CA (1) CA2846240C (enExample)
ES (1) ES2643397T3 (enExample)
MX (1) MX350335B (enExample)
RU (1) RU2614252C2 (enExample)
SG (1) SG2014014237A (enExample)
WO (1) WO2013026004A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
ES2779412T3 (es) * 2014-06-17 2020-08-17 Medimmune Ltd Anticuerpos Alfa-V Beta-8 mejorados
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
CN109862913B (zh) 2016-09-29 2023-09-05 加利福尼亚大学董事会 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
EP3630185A4 (en) * 2017-05-30 2020-06-17 The Board of Trustees of the Leland Stanford Junior University TREATMENT OF A NEUROINFLAMMATIONAL DISEASE
CN112823167B (zh) 2018-09-07 2025-07-15 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
BR112021009325A2 (pt) * 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
TWI854088B (zh) 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
WO2024056668A1 (en) * 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
KR20250167591A (ko) * 2023-03-31 2025-12-01 제넨테크, 인크. 항-알파 v 베타 8 인테그린 항체 및 사용 방법
WO2024258908A1 (en) * 2023-06-12 2024-12-19 University Of Washington De novo designed alpha (v) beta (8) integrin selective minibinder
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0575554A1 (en) * 1991-03-14 1993-12-29 Genentech, Inc. Novel beta integrin subunit
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
JP4653660B2 (ja) * 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
US20110250203A1 (en) * 2008-08-29 2011-10-13 Symphogen A/S Anti-cd5 antibodies
BR112012003686B1 (pt) * 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY

Also Published As

Publication number Publication date
MX350335B (es) 2017-09-04
US20140271478A1 (en) 2014-09-18
KR20140054238A (ko) 2014-05-08
BR112014003501B1 (pt) 2022-02-08
CN103857696B (zh) 2017-07-04
AU2012296362A1 (en) 2014-03-13
MX2014001850A (es) 2014-12-08
WO2013026004A3 (en) 2013-06-13
AU2012296362B2 (en) 2017-06-29
KR102010098B1 (ko) 2019-08-13
WO2013026004A2 (en) 2013-02-21
EP2744823B1 (en) 2017-08-02
US9492569B2 (en) 2016-11-15
RU2014109928A (ru) 2015-09-27
JP2015501285A (ja) 2015-01-15
EP2744823A4 (en) 2015-08-12
RU2614252C2 (ru) 2017-03-24
JP6093360B2 (ja) 2017-03-08
ES2643397T3 (es) 2017-11-22
CN103857696A (zh) 2014-06-11
SG2014014237A (en) 2014-07-30
CA2846240A1 (en) 2013-02-21
BR112014003501A2 (pt) 2017-03-01
EP2744823A2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
AU2012296362B2 (en) Antibodies that bind integrin alpha-v beta-8
US12110334B2 (en) Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
US20150315279A1 (en) Antibodies that bind membrane-bound il1rap
KR20150023355A (ko) Ｃｌｌ-1 에 특이적인 항체
US12195540B2 (en) Antibodies that bind integrin αvβ8 and uses thereof
US20160185856A1 (en) Anti-Claudin 1 Antibodies and Uses Thereof
HK1196971A (en) Antibodies that bind integrin alpha-v beta-8
HK1196971B (en) Antibodies that bind integrin alpha-v beta-8
HK40008779A (en) NEUTRALIZING ANTIBODIES TO THE αVβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
HK40008779B (en) NEUTRALIZING ANTIBODIES TO THE αvβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170720

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260401